Latest news
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - MoomooMoomoo · Sun, 09 Aug 2026 11:18:08 GMTRevolution Medicines Earns Buy as Strong RAS Portfolio Data, Robust Launch Prep, and $5.4B Capital Base Drive Price Target Increase to $291 - TipRanksTipRanks · Thu, 06 Aug 2026 02:35:51 GMTAnalyst Backs Crescent Biopharma With Buy Rating on Advancing ADC Pipeline and Strong Cash Runway - TipRanksTipRanks · Thu, 30 Jul 2026 07:00:00 GMT